Iovance Biotherapeutics (IOVA) Expected to Announce Earnings on Thursday
by Renee Jackson · The Cerbat GemIovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) is projected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.19) per share and revenue of $77.8370 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Iovance Biotherapeutics Price Performance
Shares of IOVA stock traded up $0.14 during trading hours on Tuesday, reaching $3.99. 16,181,457 shares of the company were exchanged, compared to its average volume of 15,027,924. Iovance Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $5.63. The stock’s fifty day moving average is $3.77 and its two-hundred day moving average is $2.90. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -3.56 and a beta of 0.69.
Institutional Trading of Iovance Biotherapeutics
A number of institutional investors and hedge funds have recently modified their holdings of IOVA. State Street Corp boosted its stake in Iovance Biotherapeutics by 51.5% during the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after acquiring an additional 6,851,486 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Iovance Biotherapeutics by 30.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 2,032,062 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics by 16.4% in the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock valued at $21,821,000 after buying an additional 1,123,337 shares during the period. Palo Alto Investors LP increased its position in shares of Iovance Biotherapeutics by 122.1% in the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after buying an additional 4,188,803 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Iovance Biotherapeutics by 55.8% during the 3rd quarter. Bank of America Corp DE now owns 6,279,230 shares of the biotechnology company’s stock worth $13,626,000 after buying an additional 2,249,662 shares during the period. 77.03% of the stock is owned by institutional investors.
Analyst Ratings Changes
IOVA has been the subject of several research analyst reports. Truist Financial upgraded shares of Iovance Biotherapeutics to a “hold” rating in a research report on Wednesday, March 25th. UBS Group lifted their target price on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. Chardan Capital restated a “buy” rating and set a $16.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.88.
Check Out Our Latest Stock Analysis on Iovance Biotherapeutics
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.
Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.